GlassScriptPhysician profile
Joseph Gurule
NPI 1396702973
$14,556.03
in general payments reported to CMS, 2019-2025
23 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $2,533 · 2023: $4,366 · 2024: $5,036 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,285.23 |
| Education | $196.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,078.77 | 2022-2025 | |
| Dermavant Sciences, INC. | $1,787.75 | 2023-2024 | Vtama |
| Leo Pharma INC. | $1,318.91 | 2022-2024 | Adbry |
| Incyte Corporation | $986.46 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $950.22 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $835.60 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $749.84 | 2021-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $689.82 | 2022-2024 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $648.07 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $618.25 | 2022-2025 | Blu-U, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $565.46 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $539.40 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $519.53 | 2022-2025 | Sotyktu |
| Pfizer INC. | $401.15 | 2024-2025 | |
| Journey Medical Corporation | $388.29 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $368.07 | 2023-2025 | Otezla, Otezla, Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.01 | 2023-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $340.19 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.89 | 2022-2023 | Duobrii, Arazlo, Jublia |
| Janssen Scientific Affairs, LLC | $123.48 | 2022 | |
| Epi Health, LLC | $85.51 | 2022 | |
| Organon LLC | $40.08 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $15.28 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gurule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.